How should cancer be treated in an HIV-positive patient on antiretroviral therapy?

Cancer Treatment in HIV-Positive Patients on Antiretroviral Therapy

HIV-positive patients with cancer should receive the same standard, full-dose cancer treatment as HIV-negative patients, with antiretroviral therapy continued throughout cancer treatment under co-management by both an oncologist and HIV specialist. 1

Core Management Principles

Continue Antiretroviral Therapy During Cancer Treatment

• ART must be maintained throughout cancer therapy to prevent immunologic compromise, opportunistic infections, and death 1
• Continuation of ART results in better tolerance of cancer treatment, higher response rates, and improved survival 1
• ART interruptions should be avoided except in rare circumstances when alternative regimens are unavailable and drug-drug interactions cannot be managed 1

Mandatory Co-Management Structure

• All HIV-positive cancer patients require co-management by an oncologist and HIV specialist 1
• Consultation with both an HIV pharmacist and oncology pharmacist is essential to identify and manage drug-drug interactions 1
• Cancer treatment should not be delayed for HIV workup if possible 1

Antiretroviral Therapy Modifications

Specific ARVs to Avoid During Chemotherapy

High-risk agents that must be avoided or used with extreme caution: 1

• Ritonavir, cobicistat, and protease inhibitors: Avoid due to frequent adverse drug interactions
• Zidovudine: Avoid due to additive myelosuppression with chemotherapy
• Didanosine and stavudine: Avoid due to additive peripheral neuropathy
• Non-nucleoside reverse transcriptase inhibitors: Use with caution as they may decrease chemotherapy efficacy

ART Initiation Timing

• If patient is not yet on ART, initiate either ≥7 days before starting cancer treatment OR after cancer therapy tolerance is established 1
• This timing allows separate assessment of ART versus chemotherapy toxicities 1
• Exception: Start ART immediately for conditions like progressive multifocal leukoencephalopathy regardless of cancer therapy timing 1

Monitoring Requirements

Enhanced Surveillance Parameters

• HIV viral load: Monitor monthly for first 3 months, then every 3 months during cancer treatment 1
• More frequent testing is necessary because drug-drug interactions may decrease ART effectiveness 1
• CD4+ T-cell counts: Measure more frequently in patients receiving lymphopenia-inducing cancer treatments 1
• CD4+ count decreases from chemotherapy do not reflect HIV control but do predict opportunistic infection risk 1

Opportunistic Infection Prophylaxis

CD4+ Count-Based Prophylaxis Algorithm

For CD4+ <200 cells/μL: 1

• Pneumocystis jiroveci pneumonia (PJP) prophylaxis: Sulfamethoxazole-trimethoprim 800/160 mg three times weekly OR dapsone 100 mg daily 1
• Gram-negative bacterial prophylaxis: Ciprofloxacin 500-750 mg every 12 hours OR levofloxacin 500-750 mg daily 1
• Continue PJP prophylaxis until CD4+ recovers to ≥200 cells/μL for ≥3 months post-cancer therapy 1

For CD4+ <100 cells/μL: 1

• Consider dose reduction of chemotherapy in early cycles 1
• Mycobacterium avium complex (MAC) prophylaxis: Azithromycin 1200 mg weekly 1
• Continue until CD4+ recovers to ≥100 cells/μL for ≥3 months post-cancer therapy 1

For all patients receiving myelosuppressive chemotherapy: 1

• HSV/VZV prophylaxis: Acyclovir 400-800 mg twice daily OR valacyclovir 500 mg twice daily (continue until completion of cancer therapy) 1
• Candida prophylaxis: Nystatin ± fluconazole 1

Growth Factor Support

• Myeloid growth factors are required for high-risk regimens and strongly recommended for intermediate-risk regimens in HIV-positive patients 1
• Pre-existing neutropenia or low CD4+ counts increase febrile neutropenia risk, making growth factor support essential 1
• This differs from HIV-negative patients where growth factors may not be routinely recommended 1

Special Considerations for Specific Cancers

Hodgkin Lymphoma Management

• Standard ABVD chemotherapy can be used, but growth factors may be required despite concerns about bleomycin lung toxicity 1
• Dose reductions are appropriate for severe and prolonged cytopenias in HIV-positive patients (unlike standard guidelines for HIV-negative patients) 1
• Consider dropping bleomycin after 2 cycles if pulmonary symptoms develop or DLCO falls, particularly with complete PET/CT response 1

Hepatitis B Co-infection

• ART regimen must include agents that treat both HIV and hepatitis B 1
• Options include tenofovir disoproxil fumarate 300 mg daily, tenofovir alafenamide 25 mg daily, or entecavir 0.5-1 mg daily 1

Immunotherapy Considerations

• Anti-PD-1 and anti-PD-L1 agents are safe and effective in HIV-positive patients for FDA-approved indications 2
• These agents have FDA approval for Hodgkin lymphoma, cervical cancer, head and neck cancer, hepatocellular carcinoma, and non-small-cell lung cancer 2
• Prospective studies demonstrate safety and efficacy across expected cancer types and CD4+ counts 2, 3

Critical Pitfalls to Avoid

• Never reduce cancer treatment doses or withhold standard therapy based solely on HIV status 1, 4, 2
• Do not assume decreased life expectancy justifies substandard cancer care—with modern ART, life expectancy approaches that of HIV-negative individuals 1, 5, 6
• Avoid azole antifungals during chemotherapy administration due to CYP3A4 interactions; hold azoles minimum 24 hours before and after chemotherapy 1
• Do not overlook opportunistic infections as causes of fever during neutropenia—maintain high index of suspicion and test early 1
• Screen all cancer patients for HIV, as undiagnosed HIV affects treatment planning 1